COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01292252
Recruitment Status : Completed
First Posted : February 9, 2011
Last Update Posted : August 19, 2019
Eli Lilly and Company
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:
The purpose of this study is to determine the effects of 12 weeks of daily treatment with teriparatide on spine fusion in adult patients who are undergoing multi-level posterolateral spine fusion surgery for degenerative conditions of the lumbar spine.

Condition or disease Intervention/treatment Phase
Lumbar Spondylosis Lumbar Spondylolisthesis Adult Degenerative Lumbar Scoliosis Biological: teriparatide Biological: Placebo Phase 4

Detailed Description:

For patients undergoing spine fusion surgery, non-fusion (or pseudarthrosis) is one of the major complications that can lead to poor clinical outcomes. Therefore, treatments that promote or augment fusion are highly desirable. Teriparatide (Forteo, recombinant human parathyroid hormone [1-34]) is a systemically administered peptide hormone that is FDA-approved for the treatment of osteoporosis in postmenopausal women or other populations at high risk for fracture. While teriparatide has been shown to enhance spinal fusion in several rodent and rabbit studies, no clinical studies to date have examined its effect on spinal fusion in humans. While Forteo is FDA approved, and IND is required for this trial to study an unapproved indication: Posterolateral Lumbar Spine Fusion.

This single-site two-year prospective randomized double-blind placebo-controlled study is designed to examine the effects of peri-operative teriparatide treatment in older adults undergoing multi-level posterolateral lumbar spine fusion. All eligible patients seen at the UCSF Spine Center will be invited to enroll in the study. Upon enrollment, patients will have screening labs drawn in conjunction with their routine pre-operative work-up, to include complete blood count (CBC), chemistry panel including calcium level, liver function tests (LFTs) including alkaline phosphatase, parathyroid hormone (PTH) level, and 25-hydroxyvitamin D level. If eligible after screening labs are completed, they will be scheduled for bone density (DEXA) scan and be randomized in a 2:1 ratio to receive daily subcutaneous injections of teriparatide 20 ug/d or placebo. The total duration of treatment will be 12 weeks, with two weeks pre-operative and 10 weeks post-operative treatment.

Patients will be scheduled to attend all standard post-operative follow-up clinic visits, which will be at 6 weeks, 3 months, 6 months, and 12 months after surgery. At 3 months post operative visit, patients will have lab drawn for calcium. At each follow-up visit, AP and lateral x-ray radiographs will be taken of the lumber spine to assess progression of bone healing and positioning of any hardware placed. Participants will be asked to complete a pain Visual Analog Score (VAS), European Quality of Life-5 Dimensions (EQ-5D), and Oswestry Disability Index (ODI) questionnaire at each visit for assessment of clinical outcomes. Thin-section helical CT scans of the lumbar spine will be taken at 12 months after surgery for definitive assessment of fusion. All radiographs will be evaluated by a blinded panel of three reviewers including a radiologist and a spine surgeon to assess primary outcome.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Assessment of the Efficacy of Forteo (Teriparatide) in Patients Undergoing Posterolateral Lumbar Spinal Fusion
Study Start Date : August 2011
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment
Forteo, Terapeptide 20 ug subcutaneous injection
Biological: teriparatide
Teriparatide 20 ug subcutaneous injection daily for 12 weeks
Other Names:
  • Forteo
  • recombinant human parathyroid hormone (1-34)

Placebo Comparator: Control
Saline placebo
Biological: Placebo
Saline solution

Primary Outcome Measures :
  1. Quality of spine fusion [ Time Frame: One year ]
    Quality of spine fusion at one year will be assessed using thin-section helical CT scan of the lumbar spine.

  2. Time to spine fusion [ Time Frame: One year ]
    Time to spine fusion will be determined using AP/lateral x-rays of the lumbar spine taken at 6 weeks, 3 months, 6 months, and 1 year after surgery.

Secondary Outcome Measures :
  1. Clinical outcome [ Time Frame: One year ]
    Clinical outcomes will be assessed using self-reported pain Visual Analog Score (VAS), European Quality of Life - 5 Dimensions (EQ-5D), and Oswestry Disability Index (ODI) scores at the preoperative and postoperative follow-up visits.

  2. Adverse effects [ Time Frame: One year ]
    Patient-reported adverse effects of study treatment will be recorded at the time of surgery and at all post-operative follow-up visits.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients aged 60-90 years with lumbar spondylosis, spondylolithesis, or adult degenerative scoliosis, including disc pathology, stenosis, deformity, instability, or postdecompression revision, who are scheduled to undergo three-level or greater posterolateral lumbar spinal fusion.
  • Willing and able to use a pen-type delivery system to administer daily subcutaneous injections.

Exclusion Criteria:

  • Use of bone morphogenic protein (BMP) posterolaterally during the fusion procedure.
  • Previous spinal fusion at the intended fusion levels.
  • Prior use of Forteo (teriparatide).
  • Use of digoxin.
  • Paget's Disease of bone.
  • History of primary skeletal malignancy, presence of bone metastases, or previous skeletal exposure to therapeutic irradiation.
  • Elevated serum calcium, serum PTH >70 pg/ml, 25-hydroxyvitamin D <12 ng/mL, or active liver disease.
  • History of symptomatic nephro- or urolithiasis in the past two years.
  • History of malignant neoplasm in the past five years, except for superficial basal cell carcinoma or squamous cell carcinoma.
  • Carcinoma in situ of the uterine cervix treated in the past year.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01292252

Layout table for location information
United States, California
UCSF Spine Center
San Francisco, California, United States, 94143
Sponsors and Collaborators
University of California, San Francisco
Eli Lilly and Company
Layout table for investigator information
Principal Investigator: Shane Burch, MD University of California, San Francisco
Study Director: Carmen Li University of California, San Francisco
Additional Information:
Layout table for additonal information
Responsible Party: University of California, San Francisco Identifier: NCT01292252    
Other Study ID Numbers: UCSFSpineForteo
First Posted: February 9, 2011    Key Record Dates
Last Update Posted: August 19, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Curvatures
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases
Parathyroid Hormone
Physiological Effects of Drugs
Calcium-Regulating Hormones and Agents
Bone Density Conservation Agents